We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Forest Enters Into Fifth Bystolic Patent Settlement, Two Infringement Cases Outstanding
Forest Enters Into Fifth Bystolic Patent Settlement, Two Infringement Cases Outstanding
January 4, 2013
Glenmark Generics can launch a generic version of Forest Laboratories hypertension drug Bystolic — potentially as soon as Sept. 17, 2021 — under terms of a settlement of a patent infringement case between the two companies.